The total return over the past 12 months is -86.03% vs. +16.94% for the S&P 500. So far it's up -80.85% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (86.03%) | (59.17%) | (53.37%) | (35.85%) | N/A | N/A |
| Total Return CAGR | (86.03%) | (59.17%) | (53.37%) | (35.85%) | N/A | N/A |
| Revenue CAGR | N/A | (75.64%) | (42.51%) | (10.51%) | N/A | N/A |
| Net Income CAGR | (126.13%) | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Seres Therapeutics, Inc. (MCRB)
| Year | Start price | End price | MCRB Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $14.88 | $2.85 | (80.85%) | +14.51% | (95.36%) |
| 2025 | $16.62 | $14.88 | (10.47%) | +17.72% | (28.19%) |
| 2024 | $28.00 | $16.62 | (40.64%) | +24.89% | (65.53%) |
| 2023 | $112.00 | $28.00 | (75.00%) | +26.19% | (101.19%) |
| 2022 | $166.60 | $112.00 | (32.77%) | (18.17%) | (14.60%) |
| 2021 | $490.00 | $166.60 | (66.00%) | +28.74% | (94.74%) |
| 2020 | $69.00 | $490.00 | +610.14% | +18.37% | +591.77% |
| 2019 | $90.40 | $69.00 | (23.67%) | +31.22% | (54.89%) |
| 2018 | $202.80 | $90.40 | (55.42%) | (4.56%) | (50.86%) |
| 2017 | $198.00 | $202.80 | +2.42% | +21.70% | (19.28%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
